{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:40:49Z","timestamp":1776080449437,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC 03\/12"],"award-info":[{"award-number":["RC 03\/12"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-026-01199-3","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:34:48Z","timestamp":1772696088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of intravenous use of anakinra in pediatric inflammatory conditions: a retrospective multicenter study"],"prefix":"10.1186","volume":"24","author":[{"given":"Marta","family":"Klanjscek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Pardeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Caorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Dell\u2019Orso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Abu","family":"Rumeileh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelita","family":"D\u2019Ippolito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Maximova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Cattalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Taddio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Bracaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"1199_CR1","unstructured":"https:\/\/www.fda.gov\/media\/163546\/download"},{"key":"1199_CR2","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kineret-epar-product-information_en.pdf"},{"key":"1199_CR3","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720\u201332. https:\/\/doi.org\/10.1182\/blood-2010-07-273417.","journal-title":"Blood"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ejh.14029","volume":"111","author":"JEG Charlesworth","year":"2023","unstructured":"Charlesworth JEG, Kavirayani A. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: A systematic review. Eur J Haematol. 2023;111:458\u201376. https:\/\/doi.org\/10.1111\/ejh.14029.","journal-title":"Eur J Haematol"},{"key":"1199_CR5","doi-asserted-by":"publisher","first-page":"e29102","DOI":"10.1002\/pbc.29102","volume":"68","author":"JEG Charlesworth","year":"2021","unstructured":"Charlesworth JEG, Wilson S, Qureshi A, Blanco E, Mitchell A, Segal S, Kelly D, Weitz J, O\u2019Shea D, Bailey K, Kavirayani A. Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis\/macrophage activation syndrome in critically ill children. Pediatr Blood Cancer. 2021;68:e29102. https:\/\/doi.org\/10.1002\/pbc.29102.","journal-title":"Pediatr Blood Cancer"},{"key":"1199_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/rheumatology\/kead381","volume":"63","author":"A Taddio","year":"2024","unstructured":"Taddio A, Della Paolera S, Abbagnato L, Agrusti A, Badolato R, Biscaro F, Caorsi R, Consolaro A, Dellepiane RM, Fabi M, Floretta I, Gattorno M, Giangreco M, La Torre F, Maggio MC, Mambelli L, Mauro A, Mastrolia MV, Meneghel A, Montin D, Ricci F, Simonini G, Smarrazzo A, Sottile R, Stucchi S, Tardi M, Verdoni L, Zuccotti G, Zunica F, Ravelli A, Cattalini M, Italian Society of Pediatric Rheumatology (ReumaPed). Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity. Rheumatology (Oxford). 2024;63:366\u201375. https:\/\/doi.org\/10.1093\/rheumatology\/kead381.","journal-title":"Rheumatology (Oxford)"},{"key":"1199_CR7","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, Holodny A, Brentjens RJ, Riviere I, Sadelain M. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023;29:1710\u20137. https:\/\/doi.org\/10.1038\/s41591-023-02404-6.","journal-title":"Nat Med"},{"key":"1199_CR8","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","volume":"271","author":"CJ Fisher Jr","year":"1994","unstructured":"Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271:1836\u201343.","journal-title":"JAMA"},{"key":"1199_CR9","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2:e358\u201367. https:\/\/doi.org\/10.1016\/S2665-9913(20)30096-5.","journal-title":"Lancet Rheumatol"},{"key":"1199_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","volume":"74","author":"BB Yang","year":"2003","unstructured":"Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74:85\u201394. https:\/\/doi.org\/10.1016\/S0009-9236(03)00094-8.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1199_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/cts.12622","volume":"12","author":"BB Yang","year":"2019","unstructured":"Yang BB, Gozzi P, Sullivan JT. Pharmacokinetics of Anakinra in Subjects of Heavier vs. Lighter Body Weights. Clin Transl Sci. 2019;12(4):371\u20138. https:\/\/doi.org\/10.1111\/cts.12622. Epub 2019 Apr 8. PMID: 30884170; PMCID: PMC6662383.","journal-title":"Clin Transl Sci"},{"key":"1199_CR12","doi-asserted-by":"crossref","unstructured":"Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4:353\u201360. https:\/\/doi.org\/10.1016\/1043\u201346669290078-6.","DOI":"10.1016\/1043-4666(92)90078-6"},{"key":"1199_CR13","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1182\/blood.V82.10.2985.bloodjournal82102985","volume":"15","author":"EV Granowitz","year":"1993","unstructured":"Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, Lynch EA, Ye K, Poutsiaka DD, Vannier E, et al. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood. 1993;15:2985\u201390.","journal-title":"Blood"},{"key":"1199_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00003246-199401000-00008","volume":"22","author":"CJ Fisher Jr","year":"1994","unstructured":"Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA, IL-1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22:12\u201321. https:\/\/doi.org\/10.1097\/00003246-199401000-00008.","journal-title":"Crit Care Med"},{"key":"1199_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","volume":"25","author":"SM Opal","year":"1997","unstructured":"Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25:1115\u201324. https:\/\/doi.org\/10.1097\/00003246-199707000-00010.","journal-title":"Crit Care Med"},{"key":"1199_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"A Kelly","year":"2008","unstructured":"Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615\u201320. https:\/\/doi.org\/10.1038\/ncprheum0919.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1199_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cct.2016.04.002","volume":"48","author":"AH Tremoulet","year":"2016","unstructured":"Tremoulet AH, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC. Rationale and study design for a phase I\/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials. 2016;48:70\u20135. https:\/\/doi.org\/10.1016\/j.cct.2016.04.002.","journal-title":"Contemp Clin Trials"},{"key":"1199_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","volume":"31","author":"J Galea","year":"2011","unstructured":"Galea J, Ogungbenro K, Hulme S. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. 2011;31:439\u201347.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1199_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","volume":"19","author":"O Phadke","year":"2021","unstructured":"Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021;19:98. https:\/\/doi.org\/10.1186\/s12969-021-00585-3.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1199_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/00185787221142470","volume":"58","author":"L Yang","year":"2023","unstructured":"Yang L, Lowry S, Heath T. Use of Intravenous Anakinra for Management of Pediatric Cytokine Storm Syndromes at an Academic Medical Center. Hosp Pharm. 2023;58:376\u201381. https:\/\/doi.org\/10.1177\/00185787221142470.","journal-title":"Hosp Pharm"},{"key":"1199_CR21","doi-asserted-by":"publisher","first-page":"1137051","DOI":"10.3389\/fped.2023.1137051","volume":"11","author":"F Licciardi","year":"2023","unstructured":"Licciardi F, Covizzi C, Dellepiane M, Olivini N, Mastrolia MV, Lo Vecchio A, Monno V, Tardi M, Mauro A, Alessio M, Filocamo G, Cattalini M, Taddio A, Caorsi R, Marseglia GL, La Torre F, Campana A, Simonini G, Ravelli A, Montin D. Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study. Front Pediatr. 2023;11:1137051. https:\/\/doi.org\/10.3389\/fped.2023.1137051.","journal-title":"Front Pediatr"},{"key":"1199_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","volume":"146","author":"E Pontali","year":"2020","unstructured":"Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, Angelelli A, Caorsi R, Feasi M, Calautti F, Castagnola E, Rollandi GA, Ravelli A, Cassola G, Gattorno M. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol. 2020;146:213\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.002.","journal-title":"J Allergy Clin Immunol"},{"key":"1199_CR23","doi-asserted-by":"publisher","first-page":"942455","DOI":"10.3389\/fped.2022.942455","volume":"10","author":"\u015e \u00c7a\u01e7layan","year":"2022","unstructured":"\u00c7a\u01e7layan \u015e, S\u00f6nmez HE, Otar Yener G, Ba\u01e7lan E, \u00d6zt\u00fcrk K, Ulu K, Guliyeva V, Demirkol D, \u00c7akan M, \u00d6zdel S, Bukulmez H, Aktay Ayaz N, S\u00f6zeri B. Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19. Front Pediatr. 2022;10:942455. https:\/\/doi.org\/10.3389\/fped.2022.942455.","journal-title":"Front Pediatr"},{"key":"1199_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12969-023-00858-z","volume":"21","author":"BLP Dizon","year":"2023","unstructured":"Dizon BLP, Redmond C, Gotschlich EC, Sule S, Ronis T, Vazzana KM, Sherman MA, Connor R, Bosk A, Dham N, Harahsheh AS, Wells E, DeBiasi R, Srinivasalu H. Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study. Pediatr Rheumatol Online J. 2023;21:76. https:\/\/doi.org\/10.1186\/s12969-023-00858-z.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1199_CR25","unstructured":"HLH-2004. Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis Jan-Inge Henter 1, Annacarin Horne, Maurizio Aric\u00f3, R Maarten Egeler, Alexandra H Filipovich, Shinsaku Imashuku, Stephan Ladisch, Ken McClain, David Webb, Jacek Winiarski, Gritta Janka, PMID: 16937360."},{"key":"1199_CR26","unstructured":"Diagnostic guidelines for kawasaki disease on behalf of council on cardiovascular disease in the young committee on rheumatic fever endocarditis. and kawasaki disease american heart association, Circulation, Volume 103, Number 2, January 2001."},{"key":"1199_CR27","unstructured":"Multisystem inflammatory syndrome in. children and adolescents with COVID-19 Scientific brief 15 May 2020, WHO. 14."},{"key":"1199_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/acr2.11140","volume":"2","author":"TL Wampler Muskardin","year":"2020","unstructured":"Wampler Muskardin TL. Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019. ACR Open Rheumatol. 2020;2:283\u20135. https:\/\/doi.org\/10.1002\/acr2.11140.","journal-title":"ACR Open Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01199-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:40:52Z","timestamp":1776076852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01199-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01199-3","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study record review was approved by the Institutional Review Board (IRB) of the coordinating center IRCCS Burlo Garofolo (IRCCS Burlo Garofolo-03\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FDB, RC, CB, MC, GS, MG and AT have received honoraria from SOBI and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}